SCHEMBL5377250

SCHEMBL5377250

CCCC(CC)CCC=O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
TSHR P16473 6/20 0.42
CYP3A4 P08684 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA2 P00918 3/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA7 P43166 1/20 0.35
CA14 Q9ULX7 1/20 0.35
FAAH O00519 2/20 0.34
TRPV1 Q8NER1 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TDP1 Q9NUW8 3/20 0.32
MAPK1 P28482 1/20 0.32
ATM Q13315 1/20 0.31
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6859069 0.90 ALDH1A1 (0.50) ALDH1A1TSHRCYP3A4L3MBTL1CA2
SCHEMBL19455882 0.90 ALDH1A1 (0.50) ALDH1A1TSHRCYP3A4L3MBTL1CA2
SCHEMBL10897741 0.87 ALDH1A1 (0.48) ALDH1A1TSHRCYP3A4L3MBTL1CA2
SCHEMBL2452696 0.87
SCHEMBL2958422 0.86 CYP3A4 (0.53) ALDH1A1TSHRCYP3A4L3MBTL1CA2
SCHEMBL5373874 0.86 TSHR (0.50) ALDH1A1TSHRCYP3A4L3MBTL1CA2
SCHEMBL1682010 0.84 ALDH1A1 (0.43) ALDH1A1TSHRCYP3A4L3MBTL1FAAH
SCHEMBL8349861 0.84 TSHR (0.50) ALDH1A1TSHRCYP3A4L3MBTL1CA2
SCHEMBL29008641 0.84 CYP3A4 (0.52) ALDH1A1TSHRCYP3A4L3MBTL1CA2
SCHEMBL1826406 0.84 TSHR (0.50) ALDH1A1TSHRCYP3A4L3MBTL1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116375567-A Method for manufacturing multi-branched high carbonic acid 浙江信汇新材料股份有限公司 2023-07-04 CN claimed
US-5352689-A Rhizoxin derivatives and their use as anti-tumor agents SANKYO COMPANY, LIMITED (JP) 1994-10-04 US claimed
CN-116375567-B Method for manufacturing multi-branched high carbonic acid 浙江信汇新材料股份有限公司 2024-03-26 CN disclosed
CN-116375567-A Method for manufacturing multi-branched high carbonic acid 浙江信汇新材料股份有限公司 2023-07-04 CN disclosed
WO-2023100719-A1 FULLERENE DERIVATIVE, n-TYPE SEMICONDUCTOR MATERIAL, ORGANIC POWER GENERATION LAYER AND PHOTOELECTRIC CONVERSION ELEMENT 株式会社ハーベス 2023-06-08 WO disclosed
EP-3372581-B1 FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL DAIKIN IND LTD (JP) 2021-06-23 EP disclosed
US-10894770-B2 Fullerene derivative and n-type semiconductor material DAIKIN INDUSTRIES, LTD. (JP) 2021-01-19 US disclosed
US-20180282274-A1 FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL DAIKIN INDUSTRIES, LTD. (JP) 2018-10-04 US disclosed
EP-3372581-A1 FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL Daikin Industries, Ltd. (JP) 2018-09-12 EP disclosed
CN-108137498-A Fullerene derivate and n-type semiconductor 大金工业株式会社 2018-06-08 CN disclosed
EP-1794133-B1 ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-12-14 EP disclosed
EP-1294731-B1 BISPHOSPHITE COMPOUNDS, THE METAL COMPLEXES THEREOF AND THE USE OF SAID COMPOUNDS AND COMPLEXES IN OLEFIN HYDROFORMYLATION OXENO OLEFINCHEMIE GMBH (DE) 2004-02-18 EP disclosed
EP-1294731-A1 BISPHOSPHITE COMPOUNDS, THE METAL COMPLEXES THEREOF AND THE USE OF SAID COMPOUNDS AND COMPLEXES IN OLEFIN HYDROFORMYLATION Oxeno Olefinchemie GmbH (DE) 2003-03-26 EP disclosed
WO-2002000670-A1 BISPHOSPHITE COMPOUNDS, THE METAL COMPLEXES THEREOF AND THE USE OF SAID COMPOUNDS AND COMPLEXES IN OLEFIN HYDROFORMYLATION OXENO OLEFINCHEMIE GMBH (DE) 2002-01-03 WO disclosed
US-5998635-A CATALYTIC CYCLIZATION AN ALDEHYDE WITH A KETENE TAKASAGO INTERNATIONAL CORPORATION (JP) 1999-12-07 US disclosed
US-5391564-A E.g., rhizoxin-13-yl 3-methylthiopropionate; anticarcinogenic agents SANKYO COMPANY, LIMITED (JP) 1995-02-21 US disclosed
US-5389626-A 3-aryloxmethyl-cephalosporin derivatives, and their medical use SANKYO COMPANY, LIMITED (JP) 1995-02-14 US disclosed
US-5352689-A Rhizoxin derivatives and their use as anti-tumor agents SANKYO COMPANY, LIMITED (JP) 1994-10-04 US disclosed
EP-0350315-B1 RHIZOXIN DERIVATES AND THEIR USE AS ANTI-TUMOR AGENTS SANKYO COMPANY LIMITED (JP) 1993-06-16 EP disclosed
EP-0350315-A1 Rhizoxin derivates and their use as anti-tumor agents SANKYO COMPANY LIMITED (JP) 1990-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10894770-B2 Fullerene derivative and n-type semiconductor material SUN2, NES, L1CAM ALDH1A1 1952/4885TSHR 2875/4885CYP3A4 2536/4885
US-20180282274-A1 FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL SUN2, NES, L1CAM ALDH1A1 1952/4885TSHR 2875/4885CYP3A4 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.